Androgen receptor gain in circulating free DNA and splicing variant 7 in exosomes predict clinical outcome in CRPC patients treated with abiraterone and enzalutamide.

Del Re, M; Conteduca, V; Crucitta, S; Gurioli, G; Casadei, C; Restante, G; Schepisi, G; Lolli, C; Cucchiara, F; Danesi, R; De Giorgi, U

Del Re, M; Conteduca, V; Crucitta, S; Gurioli, G; Casadei, C; Restante, G; Schepisi, G; Lolli, C; Cucchiara, F; Danesi, R; De Giorgi, U.

Afiliación

Del Re M; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Conteduca V; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Crucitta S; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Gurioli G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Casadei C; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Restante G; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Schepisi G; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Lolli C; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.
Cucchiara F; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy.
Danesi R; Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University Hospital of Pisa, Pisa, Italy. romano.danesi@unipi.it.
De Giorgi U; Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy.

Prostate Cancer Prostatic Dis ; 24(2): 524-531, 2021 06.

Article en En | MEDLINE | ID: mdl-33500577

Asunto(s)

Empalme Alternativo; Androstenos/uso terapéutico; Benzamidas/uso terapéutico; Ácidos Nucleicos Libres de Células/genética; Exosomas/genética; Nitrilos/uso terapéutico; Feniltiohidantoína/uso terapéutico; Neoplasias de la Próstata Resistentes a la Castración/patología; Receptores Androgénicos/genética; Anciano; Anciano de 80 o más Años; Biomarcadores de Tumor/sangre; Biomarcadores de Tumor/genética; Resistencia a Antineoplásicos; Estudios de Seguimiento; Humanos; Masculino; Persona de Mediana Edad; Pronóstico; Neoplasias de la Próstata Resistentes a la Castración/sangre; Neoplasias de la Próstata Resistentes a la Castración/tratamiento farmacológico; Neoplasias de la Próstata Resistentes a la Castración/genética; Receptores Androgénicos/sangre; Estudios Retrospectivos; Tasa de Supervivencia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Feniltiohidantoína / Benzamidas / Receptores Androgénicos / Empalme Alternativo / Exosomas / Neoplasias de la Próstata Resistentes a la Castración / Ácidos Nucleicos Libres de Células / Androstenos / Nitrilos Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Aged / Aged80 / Humans / Male / Middle aged Idioma: En Revista: Prostate Cancer Prostatic Dis Asunto de la revista: ENDOCRINOLOGIA / NEOPLASIAS / UROLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Italia

Texto completo

Imprimir

XML

PubMed Links

Buscar en Google